EP1105119A2 - New use of taxoid derivatives - Google Patents

New use of taxoid derivatives

Info

Publication number
EP1105119A2
EP1105119A2 EP99944532A EP99944532A EP1105119A2 EP 1105119 A2 EP1105119 A2 EP 1105119A2 EP 99944532 A EP99944532 A EP 99944532A EP 99944532 A EP99944532 A EP 99944532A EP 1105119 A2 EP1105119 A2 EP 1105119A2
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
radical
radicals
alkyl
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99944532A
Other languages
German (de)
French (fr)
Inventor
Marie-Christine Bissery
Patricia Vrignaud
Simon Roberts
Clive Brealey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98115650A external-priority patent/EP0982028A1/en
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of EP1105119A2 publication Critical patent/EP1105119A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Definitions

  • the present invention relates a new use of taxoid derivatives. It relates more precisely to a method for treating abnormal cell proliferation of different resistant cell lines expressing multidrug resistance P-glycoprotein. This type of cells are representative of colon cancer cells.
  • the present invention is related to the treatment of abnormal cell proliferation of different resistant cell lines expressing multidrug resistance P-glycoprotein and is also related to the treatment of abnormal cell proliferation of different resistant cell lines expressing multidrug resistance P- glycoprotein and is also related to the treatment of colon tumors of mammals including men by administrating a compound of general formula (I) or a pharmaceutically acceptable salt or solvante thereof :
  • Z represents a hydrogen atom or a radical of general formula :
  • R represents a benzoyl radical optionally substituted with one or more identical or different atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms or trifluoromethyl radicals, a thenoyl or furoyl radical or a radical R 2 -O-CO- in which R 2 represents :
  • bicycloalkyl radical containing 7 to 10 carbon atoms these radicals being optionally substituted with one or more substituents chosen from halogen atoms and hydroxyl radicals, alkoxy radicals containing 1 to 4 carbon atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, piperidino or morpholino radicals, 1-piperazinyl radicals (optionally substituted at position 4 with an alkyl radical containing 1 to 4 carbon atoms or with a phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms), cycloalkyl radicals containing 3 to 6 carbon atoms, cycloalkenyl radicals containing 4 to 6 carbon atoms, phenyl radicals (optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atom
  • R 3 represents an unbranched or branched alkyl radical containing 1 to 8 carbon atoms, an unbranched or branched alkenyl radical containing 2 to 8 carbon atoms, an unbranched or branched alkynyl radical containing 2 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a phenyl or ⁇ - or ⁇ -naphthyl radical optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl, alkenyl, alkynyl, aryl, aralkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxy
  • R 4 represents an alkoxy radical containing 1 to 6 carbon atoms in an unbranched or branched chain, an alkenyloxy radical containing 3 to 6 carbon atoms in an unbranched or branched chain, an alkynyloxy radical containing 3 to 6 carbon atoms in an unbranched or branched chain, a cycloalkyloxy radical containing 3 to 6 carbon atoms or a cycloalkenyloxy radical containing 4 to 6 carbon atoms, these radicals being optionally substituted with one or more halogen atoms or with an alkoxy radical containing 1 to 4 carbon atoms, an alkylthio radical containing 1 to 4 carbon atoms or a carboxyl radical, an alkyloxycarbonyl radical in which the alkyl portion contains 1 to 4 carbon atoms, a cyano or carbamoyl radical or an N-alkylcarbamoyl or N,N-dialkylcarbamoyl radical in which each alkyl
  • the aryl radicals which can be represented by R 3 are phenyl or ⁇ - or ⁇ -naphthyl radicals optionally substituted with one or more atoms or radicals chosen from halogen atoms (fluorine, chlorine, bromine, iodine) and alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxyl, hydroxyalkyl, mercapto, formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino, alkylamino, dialkylamino, carboxyl, alkoxycarbonyl, carbamoyl, dialkylcarbamoyl, cyano, nitro and trifluoromethyl radicals, on the understanding that the alkyl radicals and the alkyl portions of the other radicals contain 1 to 4 carbon atoms
  • the radicals R 4 and R 5 which may be identical or different, represent unbranched or branched alkoxy radicals containing 1 to 6 carbon atoms, optionally substituted with a methoxy, ethoxy, ethylthio, carboxyl, methoxycarbonyl, ethoxycarbonyl, cyano, carbamoyl, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-pyrrolidinocarbonyl or N-piperidinocarbonyl radical.
  • the present invention relates to the products of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) in which R, represents a benzoyl radical or a radical R 2 -O-CO- in which R 2 represents a tert-butyl radical and R 3 represents an alkyl radical containing 1 to 6 carbon atoms, an alkenyl radical containing 2 to 6 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a phenyl radical optionally substituted with one or more identical or different atoms or radicals chosen from halogen atoms (fluorine, chlorine) and alkyl (methyl), alkoxy (methoxy), dialkylamino (dimethylamino), acylamino (acetylamino), alkoxycarbonylamino (tert-butoxycarbonylamino) or trifluoromethyl radicals, or a 2- or 3-furyl, 2- or 3-thieny
  • the present invention relates to the products of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) in which R, represents a benzoyl radical or a radical R 2 -O-CO- in which R- j represents a tert-butyl radical and R 3 represents an isobutyl, isobutenyl, butenyl, cyclohexyl, phenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl or 5-thiazolyl radical, and R 4 and R 5 , which may be identical or different, each represent a methoxy, ethoxy or propoxy radical.
  • R 3 represents a phenyl radical and Ri represents a ter-butoxycarbonyl radical
  • R-t and R 5 which may be identical or different, represent a methoxy, ethoxy or propoxy radical.
  • the present invention relates to 4 ⁇ -acetoxy-2 ⁇ - benzoyloxy-5 ⁇ ,20-epoxy- 1 ⁇ -hydroxy-7 ⁇ , 1 O ⁇ -dimethoxy-9-oxo- 11 -taxen- 13 ⁇ -yl (2R,3S)-3 tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate of formula (la)
  • R-X (IV) in which R represents a radical as defined above and X represents a reactive ester residue such as a sulphuric or sulphonic ester residue or a halogen atom, to give a product bearing the unit -OR in position 10 and silyl groups in positions 7 and 13.
  • the silyl protecting groups are replaced with hydrogen atoms to give a compound still bearing the group -OR in position 10 and OH groups in positions 7 and 13.
  • the latter derivative is etherified selectively in position 7 by reaction with the derivative of formula IV to give the derivative of formula (I) in which Z is equal to hydrogen.
  • the final step consists in esterifying in position 13, according to a process which is known per se, the derivatives of formula (la), in which Z represents hydrogen, in the presence of a ⁇ -lactam according, for example, to the process described in patent EP 617,018, or in the presence of an oxazolidine as described, for example, in patent WO 96/30355 mentioned above.
  • the final step, which allows the desired compound of formula (la) to be obtained, is carried out on the intermediate compound obtained above, by the action of activated Raney nickel.
  • the action of the reagent formed in situ from sulphoxide of general formula (V), preferably dimethyl sulphoxide and acetic anhydride, is carried out in the presence of acetic acid or an acetic acid derivative such as a haloacetic acid, at a temperature of between 0 and 50°C.
  • the action of the activated Raney nickel in the presence of an aliphatic alcohol or an ether is carried out at a temperature of between -10 and 60°C.
  • A represents hydrogen or a side chain of formula (Ha) below :
  • G represents a protecting group for the hydroxyl function
  • R, and R 3 have the same meaning as in formula (II) or an oxazolidine unit of formula (Id) :
  • R, and R 3 have the same meaning as in formula (II)
  • R a and R b which may be identical or different, represent hydrogen or alkyl, aryl, halo, alkoxy, arylalkyl, alkoxyaryl, haloalkyl, haloaryl, it being possible for the substituents optionally to form a 4- to 7-membered ring.
  • 10-deacetylbaccatin as starting material, i.e. the product of formula (III), which allows appreciable economy as regards the process and moreover avoids the intermediate protection and deprotection steps necessary in the old processes.
  • ethers and preferably ethers such as methoxymethyl ether, 1-ethoxyethyl ether, benzyloxymethyl ether, p-methoxybenzyloxymethyl ether, benzyl ethers optionally substituted with one or more groups such as methoxy, chloro, nitro, 1-methyl- 1 -methoxy ethyl ether, 2-(trimethylsilyl)ethoxymethyl ether, tetrahydropyranyl ether and silyl ethers such as trialkylsilyl ethers, • carbon
  • radicals R a and R b of general formula (lib) are chosen from those described in patent WO 94/07878 and the derivatives more particularly preferred are those in which R a is hydrogen and R b is a p-methoxyphenyl radical.
  • the alkylating agent is chosen from : • alkyl halides, and preferably from alkyl iodides (RI)
  • alkyl sulphates such as methyl sulphate
  • oxoniums such as trialkyloxonium boric salts, in particular trimethyloxonium tetrafluoroborate (Me 3 OBF 4 ).
  • Methyl iodide is preferably used.
  • the alkylating agent is used in the presence of an anionization agent such as one or more strong bases, in anhydrous medium.
  • alkali metal hydrides such as sodium or potassium hydride
  • alkali metal alkoxides such as potassium tert-butoxide
  • methyl iodide in the presence of potassium hydride.
  • the reaction is preferably carried out in an organic medium which is inert under the reaction conditions.
  • organic medium which is inert under the reaction conditions.
  • solvents it is preferred to use :
  • polar aprotic solvents such as dimethylformamide, or aromatic solvents such as toluene
  • alkylesters such as ethylacetate.
  • a molar ratio between the anionization agent and the substrate of greater than 2 and preferably between 2 and 20.
  • a molar ratio between the alkylating agent and the substrate of greater than 2 and preferably between 2 and 40.
  • reaction temperature between -30°C and 80°C.
  • reaction time advantageously ranges between a few hours and 48 hours depending on the reagents chosen.
  • the process then proceeds, in a known manner, to the esterification step according, for example, to the processes described in patents EP 617,018 or WO 96/30355 mentioned above.
  • the procedure first begins with the dialkylation of 10-deacetylbaccatin, using an alkylating agent in the presence of a strong base, in a second step, the 10-deacetylbaccatin dietherified in positions 7 and 10 is coupled, in position 13, with a suitably protected ⁇ -lactam in the presence of an activating agent chosen from tertiary amines and metal bases which ensure the formation of an alkoxide in position 13. Deprotection of the side chain is then achieved by the action of an inorganic or organic acid.
  • the procedure first begins with the dialkylation of 10-deacetylbaccatin, using an alkylating agent in the presence of a strong base, in a second step, the 10-deacetylbaccatin dietherified in positions 7 and 10 is coupled, in position 13, with an oxazolidine in the presence of a coupling agent such as diimides in the presence of an activating agent such as dialkylaminopyridines. Opening of the oxazolidine is achieved by the action of an inorganic or organic acid.
  • the procedure begins with the esterification in position 13 of baccatin suitably protected in positions 7 and 10, with a ⁇ -lactam or an oxazolidine in the presence of a coupling agent and/or an activating agent as described in the above two processes.
  • the dietherification in positions 7 and 10 is carried out by an alkylating agent in the presence of a strong base. Deprotection of the side chain is then achieved by the action of an inorganic or organic acid.
  • the compounds of formula I have anti-tumor properties, more particularly, activity against tumors which are resistant to Taxol® and Taxotere®.
  • tumors include, for example, colon tumors which have an elevated expression of multidrug resistance P-glycoprotein.
  • Multi-drug resistance is the usual term relating to the resistance by a tumor against various compounds having differing structures and mechanisms of action.
  • Taxoids are generally known to be highly recognized by experimental tumors such as P388/DOX, a P388 murine leukemia cell line selected for doxorubicin (DOX) resistance, which express P-glycoprotein.
  • the compounds according to the present invention are less recognized by P388/DOX. More particularly, the compounds are less recognized than Taxotere®.
  • the compounds of formula (I) are mainly used for preparing a medecine for treating abnormal cell proliferation of cell lines expressing the multidrug resistance P-glycoprotein.
  • the compound of formula I are mainly used for preparing a medecine for treating colon cancer.
  • the compound and mainly compound of formula (I) where P and R 5 are each methoxy has the property to be active compared to the other known taxoids such as Taxol® or Taxotere® to treat the cancer cells lines expressing the multidrug resistance P-glycoprotein. It is also active against tumor cells resistant to
  • the product of formula (I) can be used concurrently with at least other therapeutic treatment. It is more preferably used with other therapeutic treatment comprising antineoplastic drugs, monoclonal antibodies, immunotherapies, radiotherapies, or biological response modifiers.
  • the product of formula (I) is preferably administered by parenteral administration such as intravenous, intraperitoneal, intramuscular or subcutaneous administration.
  • Product of formula (la) is a potent anti-cancer agent in pre-clinical models. In vitro antiproliferative properties on resistant cell lines
  • Docetaxel was found to be cross-resistant to cell lines expressing the multidrug resistance P-glycoprotein (RIGEL I. and HORWITZ S.B., Studies with RP 56976 (Taxotere®: a semisynthtetic analogue of Taxol, J. Natl. Cancer Inst, 83, 288-291, 1991).
  • the cytotoxicity of product la was examined against different resistant cell lines expressing the multidrug resistance P-glycoprotein, in comparison with docetaxel after 4 days of continuous exposure using standard methods.
  • the resistance factor was calculated by dividing the IC50 value obtained on resistant cells by the IC50 value obtained on sensitive cells.
  • product of formula la was found more active than docetaxel on all the resistant tumor cell lines which have been evaluated. Interestingly, product of formula la was found minimally cross-resistant (resistance factor: 1.8 to 4.3) in the P388/TXT, P388 NCR, HL60/TAX and Calcl8/TXT cell lines that are moderately cross- resistant to docetaxel (resistance factor: 4.8 to 23.5) and which could be more representative of the clinical situation.
  • Product of formula la was also evaluated on the murine P388/CPT5 cell line with acquired resistance to camptothecin that do not express the P-glycoprotein. A strong decrease in the cross-resistance was found for product of formula la and docetaxel (resistance factor: 4.8 and 10.5) as compared to camptothecin (resistance factor: 286). This result suggests a potential application of product of formula la in the treatment of tumors with acquired resistance to camptothecin derivatives.
  • the antiproliferative properties of the product of formula la and docetaxel were examined on the human colon adenocarcinoma CaCo-2 cell line (ATCC HTB37) that was shown to present a basal level of expression of P-glycoprotein encoded by the mdrl gene.
  • the methodology was used, i.e., 96 well plates, time of contact of the drugs (96 hours) and neutral red coloration of viable cell. Results expressed as IC50, were summarized in the next table.
  • Product of formula la is cytotoxic on CaCo-2 cells with IC50 included in the range described on the other human cell line tested, i.e., HL60, Calcl ⁇ and KB (see previous paragraph).
  • IC50 included in the range described on the other human cell line tested, i.e., HL60, Calcl ⁇ and KB (see previous paragraph).
  • docetaxel displays a higher IC50 on CaCo-2 cells, corresponding to 4.9 times the values observed with Product of formula la. Therefore, the higher antiproliferative activity of Product of formula la, compared to docetaxel, on CaCo-2 cells is in agreement with a lower recognition of Product of formula la than docetaxel by the P-glycoprotein intrinsically expressed by this cell line.
  • T/C tumor growth inhibition
  • T/C > 42 %, - is inactive
  • a T/C ⁇ _42 %, + is the minimum level for activity.
  • a T/C ⁇ 10 %, ++ is considered as a high antitumor activity level which justifies further development (DN-2 level).
  • DN-2 level the two following end points were also used: - tumor growth delay, T-C, where T and C are the median times in days required for the treatment group and the control group tumors to reach a predetermined size (750 to l500 mg).
  • regressions can be either partial (more than 50 % reduction in tumor mass) or complete. Complete regressions are included in the partial regressions.
  • the end point used for assessing activity in intraperitoneally implanted leukemia was percent increase in host life span (% ILS), calculated in relation to median day of death.
  • the NCI criteria for activity are as follows:
  • Toxicity was based on drug deaths (> 10 %) or a weight loss nadir > 20 %. Docetaxel was used for comparison trials when needed. Colon tumors
  • Colon 51 Product of formula la was administered i.v. on day 4, 6, 8. At the HNTD (9.3 mg/kg/injection), it was found highly active with a 0 % T/C and a 2.6 log cell kill. The dosage below yielded a 2.2 log cell kill. Docetaxel was also found highly active with a 3.1 log cell kill.
  • HNTD highest nontoxic dose
  • bwl body weight loss
  • DD drug death
  • bwl body weight loss.
  • HNTD highest nontoxic dose
  • bwl body weight loss
  • DD drug death
  • TFS tumor free survivors observed on day 139.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates a new use of taxoid derivatives. It relates more precisely to a method for treating abnormal cell proliferation of different resistant cell lines expressing multidrug resistance P-glycoprotein. This type of cells are representative of colon cancer cells. The products of the present invention are also usable to treat the colon cancer of mammals including men. The preferred compound is 4α-acetoxy-2α-benzoyloxy-5β, 20-epoxy-1β-hydroxy-7β-dimethoxy-9-oxo-11-taxen-13α-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate.

Description

NEW USE OF TAXOID DERIVATIVES
The present invention relates a new use of taxoid derivatives. It relates more precisely to a method for treating abnormal cell proliferation of different resistant cell lines expressing multidrug resistance P-glycoprotein. This type of cells are representative of colon cancer cells. The present invention is related to the treatment of abnormal cell proliferation of different resistant cell lines expressing multidrug resistance P-glycoprotein and is also related to the treatment of abnormal cell proliferation of different resistant cell lines expressing multidrug resistance P- glycoprotein and is also related to the treatment of colon tumors of mammals including men by administrating a compound of general formula (I) or a pharmaceutically acceptable salt or solvante thereof :
in which :
Z represents a hydrogen atom or a radical of general formula :
in which :
R, represents a benzoyl radical optionally substituted with one or more identical or different atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms or trifluoromethyl radicals, a thenoyl or furoyl radical or a radical R2-O-CO- in which R2 represents :
- an alkyl radical containing 1 to 8 carbon atoms,
- an alkenyl radical containing 2 to 8 carbon atoms, - an alkynyl radical containing 3 to 8 carbon atoms,
- a cycloalkyl radical containing 3 to 6 carbon atoms,
- a cycloalkenyl radical containing 4 to 6 carbon atoms or
- a bicycloalkyl radical containing 7 to 10 carbon atoms, these radicals being optionally substituted with one or more substituents chosen from halogen atoms and hydroxyl radicals, alkoxy radicals containing 1 to 4 carbon atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, piperidino or morpholino radicals, 1-piperazinyl radicals (optionally substituted at position 4 with an alkyl radical containing 1 to 4 carbon atoms or with a phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms), cycloalkyl radicals containing 3 to 6 carbon atoms, cycloalkenyl radicals containing 4 to 6 carbon atoms, phenyl radicals (optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atoms), cyano or carboxyl radicals or alkoxycarbonyl radicals in which the alkyl portion contains 1 to 4 carbon atoms, - a phenyl or α- or β-naphthyl radical optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to
4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atoms, or
- a 5-membered aromatic heterocyclic radical preferably chosen from furyl and thienyl radicals, - or a saturated heterocyclic radical containing 4 to 6 carbon atoms, optionally substituted with one or more alkyl radicals containing 1 to 4 carbon atoms, R3 represents an unbranched or branched alkyl radical containing 1 to 8 carbon atoms, an unbranched or branched alkenyl radical containing 2 to 8 carbon atoms, an unbranched or branched alkynyl radical containing 2 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a phenyl or α- or β-naphthyl radical optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl, alkenyl, alkynyl, aryl, aralkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxyl, hydroxyalkyl, mercapto, formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino, alkylamino, dialkylamino, carboxyl, alkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, cyano, nitro and trifluoromethyl radicals, or a 5-membered aromatic heterocycle containing one or more identical or different hetero atoms chosen from nitrogen, oxygen and sulphur atoms and optionally substituted with one or more identical or different substituents chosen from halogen atoms and alkyl, aryl, amino, alkylamino, dialkylamino, alkoxycarbonylamino, acyl, arylcarbonyl, cyano, carboxyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl or alkoxycarbonyl radicals, on the understanding that, in the substituents of the phenyl, α- or β-naphthyl and aromatic heterocyclic radicals, the alkyl radicals and the alkyl portions of the other radicals contain 1 to 4 carbon atoms, and that the alkenyl and alkynyl radicals contain 2 to 8 carbon atoms, and that the aryl radicals are phenyl or α- or β-naphthyl radicals,
R4 represents an alkoxy radical containing 1 to 6 carbon atoms in an unbranched or branched chain, an alkenyloxy radical containing 3 to 6 carbon atoms in an unbranched or branched chain, an alkynyloxy radical containing 3 to 6 carbon atoms in an unbranched or branched chain, a cycloalkyloxy radical containing 3 to 6 carbon atoms or a cycloalkenyloxy radical containing 4 to 6 carbon atoms, these radicals being optionally substituted with one or more halogen atoms or with an alkoxy radical containing 1 to 4 carbon atoms, an alkylthio radical containing 1 to 4 carbon atoms or a carboxyl radical, an alkyloxycarbonyl radical in which the alkyl portion contains 1 to 4 carbon atoms, a cyano or carbamoyl radical or an N-alkylcarbamoyl or N,N-dialkylcarbamoyl radical in which each alkyl portion contains 1 to 4 carbon atoms or, with the nitrogen atom to which it is linked, forms a saturated 5- or 6-membered heterocyclic radical optionally containing a second hetero atom chosen from oxygen, sulphur or nitrogen atoms, optionally substituted with an alkyl radical containing 1 to 4 carbon atoms or a phenyl radical or a phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms, R5 represents an alkoxy radical containing 1 to 6 carbon atoms in an unbranched or branched chain, an alkenyloxy radical containing 3 to 6 carbon atoms, an alkynyloxy radical containing 3 to 6 carbon atoms, a cycloalkyloxy radical containing 3 to 6 carbon atoms or a cycloalkenyloxy radical containing 3 to 6 carbon atoms, these radicals being optionally substituted with one or more halogen atoms or with an alkoxy radical containing 1 to 4 carbon atoms, an alkylthio radical containing 2 to 4 carbon atoms or a carboxyl radical, an alkyloxycarbonyl radical in which the alkyl portion contains 1 to 4 carbon atoms, a cyano or carbamoyl radical or an N-alkylcarbamoyl or N,N-dialkylcarbamoyl radical in which each alkyl portion contains 1 to 4 carbon atoms or, with the nitrogen atom to which it is linked, forms a saturated 5- or 6-membered heterocyclic radical optionally containing a second hetero atom chosen from oxygen, sulphur or nitrogen atoms, optionally substituted with an alkyl radical containing 1 to 4 carbon atoms or a phenyl radical or a phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms. Preferably, the aryl radicals which can be represented by R3 are phenyl or α- or β-naphthyl radicals optionally substituted with one or more atoms or radicals chosen from halogen atoms (fluorine, chlorine, bromine, iodine) and alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxyl, hydroxyalkyl, mercapto, formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino, alkylamino, dialkylamino, carboxyl, alkoxycarbonyl, carbamoyl, dialkylcarbamoyl, cyano, nitro and trifluoromethyl radicals, on the understanding that the alkyl radicals and the alkyl portions of the other radicals contain 1 to 4 carbon atoms, that the alkenyl and alkynyl radicals contain 2 to 8 carbon atoms and that the aryl radicals are phenyl or α- or β-naphthyl radicals. Preferably, the heterocyclic radicals which can be represented by R3 are
5-membered aromatic heterocyclic radicals containing one or more identical or different atoms chosen from nitrogen, oxygen and sulphur atoms, optionally substituted with one or more identical or different substituents chosen from halogen atoms (fluorine, chlorine, bromine, iodine) and alkyl radicals containing 1 to 4 carbon atoms, aryl radicals containing 6 to 10 carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms, aryloxy radicals containing 6 to 10 carbon atoms, amino radicals, alkylamino radicals containing 1 to 4 carbon atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, acylamino radicals in which the acyl portion contains 1 to 4 carbon atoms, alkoxycarbonylamino radicals containing 1 to 4 carbon atoms, acyl radicals containing 1 to 4 carbon atoms, arylcarbonyl radicals in which the aryl portion contains 6 to 10 carbon atoms, cyano, carboxyl or carbamoyl radicals, alkylcarbamoyl radicals in which the alkyl portion contains 1 to 4 carbon atoms, dialkylcarbamoyl radicals in which each alkyl portion contains 1 to 4 carbon atoms or alkoxycarbonyl radicals in which the alkoxy portion contains 1 to 4 carbon atoms.
Preferably, the radicals R4 and R5, which may be identical or different, represent unbranched or branched alkoxy radicals containing 1 to 6 carbon atoms, optionally substituted with a methoxy, ethoxy, ethylthio, carboxyl, methoxycarbonyl, ethoxycarbonyl, cyano, carbamoyl, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-pyrrolidinocarbonyl or N-piperidinocarbonyl radical.
More specially, the present invention relates to the products of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) in which R, represents a benzoyl radical or a radical R2-O-CO- in which R2 represents a tert-butyl radical and R3 represents an alkyl radical containing 1 to 6 carbon atoms, an alkenyl radical containing 2 to 6 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a phenyl radical optionally substituted with one or more identical or different atoms or radicals chosen from halogen atoms (fluorine, chlorine) and alkyl (methyl), alkoxy (methoxy), dialkylamino (dimethylamino), acylamino (acetylamino), alkoxycarbonylamino (tert-butoxycarbonylamino) or trifluoromethyl radicals, or a 2- or 3-furyl, 2- or 3-thienyl or 2-, 4- or 5-thiazolyl radical, and R4 and R5, which may be identical or different, each represent an unbranched or branched alkoxy radical containing 1 to 6 carbon atoms. Still more specially, the present invention relates to the products of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) in which R, represents a benzoyl radical or a radical R2-O-CO- in which R-j represents a tert-butyl radical and R3 represents an isobutyl, isobutenyl, butenyl, cyclohexyl, phenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl or 5-thiazolyl radical, and R4 and R5, which may be identical or different, each represent a methoxy, ethoxy or propoxy radical.
Of even more special interest are the products of general formula (I) in which R3 represents a phenyl radical and Ri represents a ter-butoxycarbonyl radical, R-t and R5, which may be identical or different, represent a methoxy, ethoxy or propoxy radical.
In a still higher interest, the present invention relates to 4α-acetoxy-2α- benzoyloxy-5 β,20-epoxy- 1 β-hydroxy-7β , 1 Oβ-dimethoxy-9-oxo- 11 -taxen- 13α-yl (2R,3S)-3 tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate of formula (la)
It is known, from patent WO 96/30355, to prepare a derivative according to the present invention by two processes. According to a first, multi-step process, starting with 10-deacetylbaccatin III of formula :
it is selectively protected in positions 7 and 13, for example in the form of a silyl diether, followed by the action of a product of general formula:
R-X (IV) in which R represents a radical as defined above and X represents a reactive ester residue such as a sulphuric or sulphonic ester residue or a halogen atom, to give a product bearing the unit -OR in position 10 and silyl groups in positions 7 and 13.
Next, the silyl protecting groups are replaced with hydrogen atoms to give a compound still bearing the group -OR in position 10 and OH groups in positions 7 and 13. The latter derivative is etherified selectively in position 7 by reaction with the derivative of formula IV to give the derivative of formula (I) in which Z is equal to hydrogen. The final step consists in esterifying in position 13, according to a process which is known per se, the derivatives of formula (la), in which Z represents hydrogen, in the presence of a β-lactam according, for example, to the process described in patent EP 617,018, or in the presence of an oxazolidine as described, for example, in patent WO 96/30355 mentioned above. After deprotection of the protecting groups in positions 7 and 10, an ester of formula (la) is thus obtained in which Z is other than hydrogen and R represents hydrogen. The next step consists in reacting the positions 7 and 10 simultaneously by the action of a reagent formed in situ from a sulphoxide of formula (V) and acetic anhydride (Pummerer-type reaction),
R-SO-R (V) in which R has the same meaning as above, to form an alkylthioalkyloxy-type intermediate on positions 7 and 10.
The final step, which allows the desired compound of formula (la) to be obtained, is carried out on the intermediate compound obtained above, by the action of activated Raney nickel.
Generally, the action of the reagent formed in situ from sulphoxide of general formula (V), preferably dimethyl sulphoxide and acetic anhydride, is carried out in the presence of acetic acid or an acetic acid derivative such as a haloacetic acid, at a temperature of between 0 and 50°C.
Generally, the action of the activated Raney nickel in the presence of an aliphatic alcohol or an ether is carried out at a temperature of between -10 and 60°C.
In the FR 97-14442 application a further process has been described. This invention allows, in a single step, the direct, selective and simultaneous alkylation of the two hydroxyl functions in positions 7 and 10 of 10-deacetylbaccatin or of derivatives thereof esterified in position 13, of formula (VI)
in which A represents hydrogen or a side chain of formula (Ha) below :
in which G represents a protecting group for the hydroxyl function, R, and R3 have the same meaning as in formula (II) or an oxazolidine unit of formula (Id) :
in which R, and R3 have the same meaning as in formula (II), Ra and Rb, which may be identical or different, represent hydrogen or alkyl, aryl, halo, alkoxy, arylalkyl, alkoxyaryl, haloalkyl, haloaryl, it being possible for the substituents optionally to form a 4- to 7-membered ring.
It is preferred to use 10-deacetylbaccatin as starting material, i.e. the product of formula (III), which allows appreciable economy as regards the process and moreover avoids the intermediate protection and deprotection steps necessary in the old processes.
Among the groups G for protecting the hydroxyl function of formula (Ha), it is generally preferred to choose all of the protecting groups described in books such as Greene and Wuts, Protective Groups in Organic Synthesis, 1991, John Wiley & Sons, and MacOmie, Protective Groups in Organic Chemistry, 1975, Plenum Press, and which are deprotected under conditions which degrade the rest of the molecule little or not at all, such as, for example: • ethers, and preferably ethers such as methoxymethyl ether, 1-ethoxyethyl ether, benzyloxymethyl ether, p-methoxybenzyloxymethyl ether, benzyl ethers optionally substituted with one or more groups such as methoxy, chloro, nitro, 1-methyl- 1 -methoxy ethyl ether, 2-(trimethylsilyl)ethoxymethyl ether, tetrahydropyranyl ether and silyl ethers such as trialkylsilyl ethers, • carbonates such as trichloroethyl carbonates.
More particularly, the radicals Ra and Rb of general formula (lib) are chosen from those described in patent WO 94/07878 and the derivatives more particularly preferred are those in which Ra is hydrogen and Rb is a p-methoxyphenyl radical.
The alkylating agent is chosen from : • alkyl halides, and preferably from alkyl iodides (RI)
• alkyl sulphates such as methyl sulphate
• oxoniums such as trialkyloxonium boric salts, in particular trimethyloxonium tetrafluoroborate (Me3OBF4).
Methyl iodide is preferably used. The alkylating agent is used in the presence of an anionization agent such as one or more strong bases, in anhydrous medium.
Among the bases which can be used in anhydrous medium, mention may be made of :
• alkali metal hydrides such as sodium or potassium hydride • alkali metal alkoxides such as potassium tert-butoxide
• silver oxide Ag2O
• 1 ,8-bis(dimethylamino)naphthalene
• mono- or dimetallic base mixtures such as those described, for example, in publications such as P. Caubere Chem. Rev. 1993, 93, 2317-2334 or M. Schlosser Mod. Synth. Methods (1992), 6, 227-271; in particular the alkyllithium/alkali metal t-butoxide or alkali metal amide/alkali metal t-butoxide combinations are preferred. One of the two bases can be generated "in situ".
Among all of the possible combinations of alkylating agent and anionization agent, it is preferred to use methyl iodide in the presence of potassium hydride.
The reaction is preferably carried out in an organic medium which is inert under the reaction conditions. Among the solvents, it is preferred to use :
• ethers such as tetrahydrofuran or dimethoxyethane
• when silver oxide is used, it is preferred to use polar aprotic solvents such as dimethylformamide, or aromatic solvents such as toluene
• when l,8-bis(dimethylamino)naphthalene is used, it is preferred to use alkylesters such as ethylacetate.
For better implementation of the invention, it is preferred to use a molar ratio between the anionization agent and the substrate of greater than 2 and preferably between 2 and 20.
It is also preferred to use a molar ratio between the alkylating agent and the substrate of greater than 2 and preferably between 2 and 40.
It is preferred to use a reaction temperature of between -30°C and 80°C.
The reaction time advantageously ranges between a few hours and 48 hours depending on the reagents chosen.
After the alkylating step, when the latter is carried out on 10-deacetylbaccatin, the process then proceeds, in a known manner, to the esterification step according, for example, to the processes described in patents EP 617,018 or WO 96/30355 mentioned above. Thus, according to a first, 3 -step process, the procedure first begins with the dialkylation of 10-deacetylbaccatin, using an alkylating agent in the presence of a strong base, in a second step, the 10-deacetylbaccatin dietherified in positions 7 and 10 is coupled, in position 13, with a suitably protected β-lactam in the presence of an activating agent chosen from tertiary amines and metal bases which ensure the formation of an alkoxide in position 13. Deprotection of the side chain is then achieved by the action of an inorganic or organic acid.
Thus, according to a second, 3-step process, the procedure first begins with the dialkylation of 10-deacetylbaccatin, using an alkylating agent in the presence of a strong base, in a second step, the 10-deacetylbaccatin dietherified in positions 7 and 10 is coupled, in position 13, with an oxazolidine in the presence of a coupling agent such as diimides in the presence of an activating agent such as dialkylaminopyridines. Opening of the oxazolidine is achieved by the action of an inorganic or organic acid. According to a third process, the procedure begins with the esterification in position 13 of baccatin suitably protected in positions 7 and 10, with a β-lactam or an oxazolidine in the presence of a coupling agent and/or an activating agent as described in the above two processes. After deprotection in positions 7 and 10, the dietherification in positions 7 and 10 is carried out by an alkylating agent in the presence of a strong base. Deprotection of the side chain is then achieved by the action of an inorganic or organic acid.
The products of general formula (I) have remarkable biological properties.
In vivo, the products of general formula (I) proved active in mice grafted with the colon adenocarcinoma C51 or C38 at doses of between 1 and 30 mg/kg, as well as on other liquid or solid tumours.
The compounds of formula I have anti-tumor properties, more particularly, activity against tumors which are resistant to Taxol® and Taxotere®. Such tumors include, for example, colon tumors which have an elevated expression of multidrug resistance P-glycoprotein. Multi-drug resistance is the usual term relating to the resistance by a tumor against various compounds having differing structures and mechanisms of action. Taxoids are generally known to be highly recognized by experimental tumors such as P388/DOX, a P388 murine leukemia cell line selected for doxorubicin (DOX) resistance, which express P-glycoprotein. The compounds according to the present invention are less recognized by P388/DOX. More particularly, the compounds are less recognized than Taxotere®.
The compounds of formula (I) are mainly used for preparing a medecine for treating abnormal cell proliferation of cell lines expressing the multidrug resistance P-glycoprotein. The compound of formula I are mainly used for preparing a medecine for treating colon cancer.
The compound and mainly compound of formula (I) where P and R5 are each methoxy has the property to be active compared to the other known taxoids such as Taxol® or Taxotere® to treat the cancer cells lines expressing the multidrug resistance P-glycoprotein. It is also active against tumor cells resistant to
Doxorubicine or resistant to Vincristine
The product of formula (I) can be used concurrently with at least other therapeutic treatment. It is more preferably used with other therapeutic treatment comprising antineoplastic drugs, monoclonal antibodies, immunotherapies, radiotherapies, or biological response modifiers.
The product of formula (I) is preferably administered by parenteral administration such as intravenous, intraperitoneal, intramuscular or subcutaneous administration.
Example 1. INTRODUCTION
Product of formula (la) is a potent anti-cancer agent in pre-clinical models. In vitro antiproliferative properties on resistant cell lines
Docetaxel was found to be cross-resistant to cell lines expressing the multidrug resistance P-glycoprotein (RIGEL I. and HORWITZ S.B., Studies with RP 56976 (Taxotere®: a semisynthtetic analogue of Taxol, J. Natl. Cancer Inst, 83, 288-291, 1991).
The cytotoxicity of product la was examined against different resistant cell lines expressing the multidrug resistance P-glycoprotein, in comparison with docetaxel after 4 days of continuous exposure using standard methods. The resistance factor was calculated by dividing the IC50 value obtained on resistant cells by the IC50 value obtained on sensitive cells.
Product of formula la was found more active than docetaxel on all the resistant tumor cell lines which have been evaluated. Interestingly, product of formula la was found minimally cross-resistant (resistance factor: 1.8 to 4.3) in the P388/TXT, P388 NCR, HL60/TAX and Calcl8/TXT cell lines that are moderately cross- resistant to docetaxel (resistance factor: 4.8 to 23.5) and which could be more representative of the clinical situation.
In addition, a strong decrease of the cross-resistance for product of formula la (resistance factor: 7.6 and 10) was found in the two most resistant to docetaxel cell lines KB VI and P388/DOX (resistance factor: 59 and 50).
Product of formula la was also evaluated on the murine P388/CPT5 cell line with acquired resistance to camptothecin that do not express the P-glycoprotein. A strong decrease in the cross-resistance was found for product of formula la and docetaxel (resistance factor: 4.8 and 10.5) as compared to camptothecin (resistance factor: 286). This result suggests a potential application of product of formula la in the treatment of tumors with acquired resistance to camptothecin derivatives.
Table 0.1 : Relative resistance of Product of formula la and docetaxel against resistant cell lines expressing the P-glycoprotein
* Relative expression obtained from Northern blot experiment using the human mdrl gene as probe. CaCo2
The antiproliferative properties of the product of formula la and docetaxel were examined on the human colon adenocarcinoma CaCo-2 cell line (ATCC HTB37) that was shown to present a basal level of expression of P-glycoprotein encoded by the mdrl gene. The methodology was used, i.e., 96 well plates, time of contact of the drugs (96 hours) and neutral red coloration of viable cell. Results expressed as IC50, were summarized in the next table.
In vitro growth inhibitory effect of Product of formula la and docetaxel on CaCo-2 cell line
*Values into brackets: number of experiments.
Product of formula la is cytotoxic on CaCo-2 cells with IC50 included in the range described on the other human cell line tested, i.e., HL60, Calclδ and KB (see previous paragraph). In contrast, docetaxel displays a higher IC50 on CaCo-2 cells, corresponding to 4.9 times the values observed with Product of formula la. Therefore, the higher antiproliferative activity of Product of formula la, compared to docetaxel, on CaCo-2 cells is in agreement with a lower recognition of Product of formula la than docetaxel by the P-glycoprotein intrinsically expressed by this cell line.
In vivo antitumor activity
In vivo schedule of administration and antitumor efficacy studies were carried out using a preclinical standard formulation of Product of formula la in ethanol: polysorbate 80 (50:50, v/v). After dilution, the final concentration was 5 % ethanol,
5 % polysorbate, 90 % glucose-5 % in water.
Subsequently, the clinical formulation was developed in which Product of formula la was solubilised in polysorbate 80. After dilution, the final polysorbate 80 concentration was 5 %. In the summaries which follow, in vivo studies were carried out using the preclinical standard formulation, unless otherwise stated. Product of formula la was administered by the intravenous route (i.v.). The experiments and data analyses were done according to standard protocols .
The activity end points used to assess subcutaneously implanted solid tumors were:
- tumor growth inhibition, T/C, where T and C are the median tumor weights in mg of the treated and the control groups, respectively. According to NCI standards, a
T/C > 42 %, -, is inactive, a T/C <_42 %, +, is the minimum level for activity. A T/C < 10 %, ++, is considered as a high antitumor activity level which justifies further development (DN-2 level). In cases of high antitumor activity, the two following end points were also used: - tumor growth delay, T-C, where T and C are the median times in days required for the treatment group and the control group tumors to reach a predetermined size (750 to l500 mg).
- log cell kill, which is the logarithm of the total number of cells killed by treatment. This value can be converted to an arbitrary rating activity according to the Southern Research Institute (SRI) : log cell kill total < 0.7 = - inactive ; 0.7-1.2 =
+ ; 1.3-1.9 = ++ ; 2.0-2.8 = +++ ; >2.8 = ++++ highly active.
For advanced stage tumors, regressions can be either partial (more than 50 % reduction in tumor mass) or complete. Complete regressions are included in the partial regressions. The end point used for assessing activity in intraperitoneally implanted leukemia was percent increase in host life span (% ILS), calculated in relation to median day of death.
The NCI criteria for activity are as follows:
- P388: highly active, ++ > 75 % ILS; active, + 27-74 % ILS; inactive, - < 27 % ILS.
Toxicity was based on drug deaths (> 10 %) or a weight loss nadir > 20 %. Docetaxel was used for comparison trials when needed. Colon tumors
Colon 51 Product of formula la was administered i.v. on day 4, 6, 8. At the HNTD (9.3 mg/kg/injection), it was found highly active with a 0 % T/C and a 2.6 log cell kill. The dosage below yielded a 2.2 log cell kill. Docetaxel was also found highly active with a 3.1 log cell kill.
Evaluation of i.v. Product of formula la against colon adenocarcinoma C51 on BALB/c female mice
Median time for tumor to reach 750 mg in control = 15.1 days.
Abbreviations used: HNTD = highest nontoxic dose, bwl = body weight loss, DD = drug death, bwl = body weight loss.
Advanced stage colon 38
Product of formula la was administered i.v. to mice bearing 200 to 400 mg of tumor. At the HNTD (20 mg/kg/injection), it was found highly active and produced 5/5 complete regressions, all mice being tumor free survivors on day 139. The dosage below (12.4 mg/kg/injection) induced the same number of complete regressions and 80 % tumor free survivors. In comparison, docetaxel at the HNTD produced only 40 % partial regressions in the same trial.
Evaluation of i.v. Product of formula la against advanced colon adenocarcinoma C38 on B6D2Fι female mice
Median time for tumor to reach 1000 mg in control = 18.5 days.
Abbreviations used: HNTD = highest nontoxic dose, bwl = body weight loss, DD = drug death, TFS = tumor free survivors observed on day 139.

Claims

C L A I M S
1 - Use of a compound of formula (I) for preparing a medecine for treating abnormal cell proliferation of cell lines expressing the multidrug resistance P-glycoprotein, said use comprising administration to a mammal of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate.
OCOC6H5
in which:
Z represents a hydrogen atom or a radical of general formula
in which :
R, represents a benzoyl radical optionally substituted with one or more identical or different atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms or trifluoromethyl radicals, a thenoyl or furoyl radical or a radical R2-O-CO- in which R, represents : an alkyl radical containing 1 to 8 carbon atoms, an alkenyl radical containing 2 to 8 carbon atoms, an alkynyl radical containing 3 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a cycloalkenyl radical containing 4 to 6 carbon atoms or a bicycloalkyl radical containing 7 to 10 carbon atoms, these radicals being optionally substituted with one or more substituents chosen from halogen atoms and hydroxyl radicals, alkoxy radicals containing 1 to 4 carbon atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, piperidino or morpholino radicals, 1-piperazinyl radicals (optionally substituted at position 4 with an alkyl radical containing 1 to 4 carbon atoms or with a phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms), cycloalkyl radicals containing 3 to 6 carbon atoms, cycloalkenyl radicals containing 4 to 6 carbon atoms, phenyl radicals (optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atoms), cyano or carboxyl radicals or alkoxycarbonyl radicals in which the alkyl portion contains 1 to 4 carbon atoms,
- a phenyl or α- or β-naphthyl radical optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atoms, or
- a 5-membered aromatic heterocyclic radical preferably chosen from furyl and thienyl radicals,
- or a saturated heterocyclic radical containing 4 to 6 carbon atoms, optionally substituted with one or more alkyl radicals containing 1 to 4 carbon atoms, R3 represents an unbranched or branched alkyl radical containing 1 to 8 carbon atoms, an unbranched or branched alkenyl radical containing 2 to 8 carbon atoms, an unbranched or branched alkynyl radical containing 2 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a phenyl or α- or β-naphthyl radical optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl, alkenyl, alkynyl, aryl, aralkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxyl, hydroxyalkyl, mercapto, formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino, alkylamino, dialkylamino, carboxyl, alkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, cyano, nitro and trifluoromethyl radicals, or a 5-membered aromatic heterocycle containing one or more identical or different hetero atoms chosen from nitrogen, oxygen and sulphur atoms and optionally substituted with one or more identical or different substituents chosen from halogen atoms and alkyl, aryl, amino, alkylamino, dialkylamino, alkoxycarbonylamino, acyl, arylcarbonyl, cyano, carboxyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl or alkoxycarbonyl radicals, on the understanding that, in the substituents of the phenyl, α- or β-naphthyl and aromatic heterocyclic radicals, the alkyl radicals and the alkyl portions of the other radicals contain 1 to 4 carbon atoms, and that the alkenyl and alkynyl radicals contain 2 to 8 carbon atoms, and that the aryl radicals are phenyl or I- or θ-naphthyl radicals,
R4 represents an alkoxy radical containing 1 to 6 carbon atoms in an unbranched or branched chain, an alkenyloxy radical contaimng 3 to 6 carbon atoms in an unbranched or branched chain, an alkynyloxy radical containing 3 to 6 carbon atoms in an unbranched or branched chain, a cycloalkyloxy radical containing 3 to 6 carbon atoms or a cycloalkenyloxy radical containing 4 to 6 carbon atoms, these radicals being optionally substituted with one or more halogen atoms or with an alkoxy radical containing 1 to 4 carbon atoms, an alkylthio radical containing 1 to 4 carbon atoms or a carboxyl radical, an alkyloxycarbonyl radical in which the alkyl portion contains 1 to 4 carbon atoms, a cyano or carbamoyl radical or an N-alkylcarbamoyl or N,N-dialkylcarbamoyl radical in which each alkyl portion contains 1 to 4 carbon atoms or, with the nitrogen atom to which it is linked, forms a saturated 5- or 6-membered heterocyclic radical optionally containing a second hetero atom chosen from oxygen, sulphur or nitrogen atoms, optionally substituted with an alkyl radical containing 1 to 4 carbon atoms or a phenyl radical or a phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms, R5 represents an alkoxy radical containing 1 to 6 carbon atoms in an unbranched or branched chain, an alkenyloxy radical containing 3 to 6 carbon atoms, an alkynyloxy radical containing 3 to 6 carbon atoms, a cycloalkyloxy radical containing 3 to 6 carbon atoms or a cycloalkenyloxy radical containing 3 to 6 carbon atoms, these radicals being optionally substituted with one or more halogen atoms or with an alkoxy radical containing 1 to 4 carbon atoms, an alkylthio radical containing 2 to 4 carbon atoms or a carboxyl radical, an alkyloxycarbonyl radical in which the alkyl portion contains 1 to 4 carbon atoms, a cyano or carbamoyl radical or an N-alkylcarbamoyl or N,N-dialkylcarbamoyl radical in which each alkyl portion contains 1 to 4 carbon atoms or, with the nitrogen atom to which it is linked, forms a saturated 5- or 6-membered heterocyclic radical optionally containing a second hetero atom chosen from oxygen, sulphur or nitrogen atoms, optionally substituted with an alkyl radical containing 1 to 4 carbon atoms or a phenyl radical or a phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms.
2 - Use of compound according to claim 1 wherein Z represents a hydrogen atom or a radical of general formula (II) in which Rj represents a benzoyl radical or a radical R2-O-CO- in which R represents a tert-butyl radical and R3 represents an alkyl radical containing 1 to 6 carbon atoms, an alkenyl radical containing 2 to 6 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a phenyl radical optionally substituted with one or more identical or different atoms or radicals chosen from halogen atoms and alkyl, alkoxy, dialkylamino, acylamino, alkoxycarbonylamino or trifluoromethyl radical, or a 2- or 3-furyl, 2- or 3-thienyl or 2-, 4- or 5-thiazolyl radical, and R4 and R5, which may be identical or different, each represent an unbranched or branched alkyloxy radical containing 1 to 6 carbon atoms.
3 - Use of a compound according to claim 2 wherein Z represents a hydrogen atom or a radical of general formula (II) in which Ri represents a benzoyl radical or a radical R2-O-CO- in which R2 represents a tert-butyl radical and R3 represents an isobutyl, isobutenyl, butenyl, cyclohexyl, phenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl or 5-thiazolyl radical, and R4 and R5, which may be identical or different, each represent a methoxy, ethoxy or propoxy radical.
4 - Use of 4α-acetoxy-2α-benzoyloxy-5β,20-epoxy-lβ-hydroxy-7β,10β-dimethoxy- 9-oxo- 11 -taxen- 13 α-yl (2R,3 S)-3 -tert-butoxycarbonylamino-2-hydroxy-3 -phenyl- propionate. for preparing a medecine for treating abnormal cell proliferation of cell lines expressing the multidrug resistance P-glycoprotein.
5 - Use of compound according to claims 1 to 4 for preparing a medecine usable to treat colon cancer.
6 - Use of compound according to claim 5 wherein this use is performed concurrently with at least other therapeutic treatment.
7 - Use of compound according to claim 6 wherein the other therapeutic treatment comprises antineoplastic drugs, monoclonal antibodies, immunotherapies, radiotherapies, or biological response modifiers.
8 - Use of compound according to claim 1 wherein the medecine is administered by parenteral administration.
9 - Use of compound of any of the claims 1 to claim 8 wherein the compound of formula (I) is administered by intravenous, intraperitoneal, intramuscular or subcutaneous administration.
EP99944532A 1998-08-20 1999-08-18 New use of taxoid derivatives Withdrawn EP1105119A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP98115650A EP0982028A1 (en) 1998-08-20 1998-08-20 New use of taxoid derivatives
EP98115650 1998-08-20
US12384399P 1999-03-11 1999-03-11
US123843P 1999-03-11
PCT/EP1999/006292 WO2000010547A2 (en) 1998-08-20 1999-08-18 New use of taxoid derivatives

Publications (1)

Publication Number Publication Date
EP1105119A2 true EP1105119A2 (en) 2001-06-13

Family

ID=26149552

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99944532A Withdrawn EP1105119A2 (en) 1998-08-20 1999-08-18 New use of taxoid derivatives

Country Status (15)

Country Link
EP (1) EP1105119A2 (en)
JP (1) JP2002523364A (en)
KR (1) KR20010079665A (en)
CN (1) CN1313764A (en)
AU (1) AU5742099A (en)
BG (1) BG105273A (en)
CA (1) CA2341191A1 (en)
EE (1) EE200100082A (en)
HU (1) HUP0104000A3 (en)
IL (1) IL141231A0 (en)
MX (1) MXPA01001721A (en)
NO (1) NO20010655D0 (en)
SK (1) SK2352001A3 (en)
TR (1) TR200100575T2 (en)
WO (1) WO2000010547A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2922107B1 (en) * 2007-10-10 2010-02-26 Aventis Pharma Sa NEW TAXOID COMPOSITIONS
CA2779009A1 (en) 2009-10-29 2011-05-05 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697522B1 (en) * 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Process for the preparation of taxane derivatives.
MA23823A1 (en) * 1995-03-27 1996-10-01 Aventis Pharma Sa NEW TAXOIDS, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM
FR2732968B1 (en) * 1995-04-14 1997-05-16 Rhone Poulenc Rorer Sa NOVEL TAXOIDS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0010547A2 *

Also Published As

Publication number Publication date
NO20010655L (en) 2001-02-07
HUP0104000A2 (en) 2002-04-29
IL141231A0 (en) 2002-03-10
SK2352001A3 (en) 2001-07-10
TR200100575T2 (en) 2001-07-23
BG105273A (en) 2001-11-30
MXPA01001721A (en) 2005-06-03
HUP0104000A3 (en) 2003-01-28
WO2000010547A2 (en) 2000-03-02
NO20010655D0 (en) 2001-02-07
CA2341191A1 (en) 2000-03-02
KR20010079665A (en) 2001-08-22
EE200100082A (en) 2002-06-17
WO2000010547A3 (en) 2000-06-29
CN1313764A (en) 2001-09-19
AU5742099A (en) 2000-03-14
JP2002523364A (en) 2002-07-30

Similar Documents

Publication Publication Date Title
AP753A (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing same.
PL189311B1 (en) Novel taxoids, method of obtaining them and pharmaceutic compositions containing such compounds
BG99713A (en) New taxoids, their preparation and pharmaceutical compositions containing them
US6346543B1 (en) Use of a taxoid to treat abnormal cell proliferation in the brain
US5547981A (en) Taxol-7-carbazates
AP1023A (en) Taxoids, preparation thereof and pharmaceutical compositions containing same.
WO2000010547A2 (en) New use of taxoid derivatives
CZ310997A3 (en) Taxoids, process of their preparation and pharmaceutical compositions containing thereof
EP0982028A1 (en) New use of taxoid derivatives
Bouchard et al. Novel taxanes: cabazitaxel case study
HUT77224A (en) New taxoids, preparation thereof and pharmaceutical compositions containing them
EP1050302A1 (en) Method for treating abnormal cell proliferation in the brain
US6403634B1 (en) Use of taxoid derivatives
CZ2001603A3 (en) Novel use of taxoid derivatives
CN113599370B (en) Application of 8-OH-DPAT and derivatives thereof in preparation of antitumor drugs
EP0982027A1 (en) Taxoid derivatives for treating abnormal cell proliferation of the brain
EP1140064A2 (en) Oral administration of taxoid derivatives
CA2365776A1 (en) Method for treating abnormal cell proliferation in the brain
Piccart Taxol and Taxotere: new drugs of interest in the treatment of advanced ovarian cancer
MXPA01001683A (en) New use of taxoid derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010213

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20010213;LV PAYMENT 20010213;MK;RO PAYMENT 20010213;SI PAYMENT 20010213

17Q First examination report despatched

Effective date: 20011107

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021004